EXEL vs GMAB: fair value comparison
Exelixis, Inc. and Genmab A/S · Updated 2026-09-07
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, EXEL currently sits closer to the top of our discount ranking.
| EXEL | GMAB | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $55.06 | $28.68 |
| 12-month range | $38.06–$55.06 | $25.45–$33.27 |
| Sector rank | #46 of 113 Healthcare | #48 of 113 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Stable | Contracting |
| Revenue growth | Strong | Declining |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Mixed |
| DCF cross-check | Undervalued | Undervalued |
| 52-week position | The top quarter | The lower-middle quarter |
Full single-stock breakdowns: EXEL fair value analysis · GMAB fair value analysis